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Acne fulminans is a rare and severe form of acne
characterized by the development of painful and
inflammatory nodules on the face, chest, and back.
Systemic signs are associated with the onset,
including fever, chills, and musculoskeletal pain.
Erythema nodosum, liver or spleen enlargement,
myositis, or aseptic bone involvement have been
reported more rarely. Its etiology remains unknown.
It is assumed that a strong activation of the cutaneous
innate immunity induced by Propionibacterium
acnes antigens could be involved. Another hypoth-
esis is that it could be a dysregulation of some
receptors expressed by sebaceous glands and kera-
tinocytes, in particular, the androgen receptors.
Moreover, these abnormalities could be genetically
determined.Fig 1. Acne fulminans on the back with nodular and
necrotic lesions.CASE REPORT
We report the case of an 18-year-old patient seen in
the outpatient setting for severe acne on his back.
In 2013, given the presence of delayed puberty
and anosmia, the diagnosis of Kallmann syndrome
was established and confirmed by olfactometry. The
serum testosterone level was 0.3 ng/mL (normal
range, 3-10 ng/mL); the luteinizing hormone level
was 0.2 IU/L (normal range, 1.7-8.6 IU); and the
follicle-stimulating hormone level was 0.1 IU/L
(normal range, 2.0 - 14.1 IU/L). His twin brother also
had Kallmann syndrome. The twins were born from a
biamniotic pregnancy with one placenta, so theythe Department of Dermatology,a and INSERM U892,b
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her authors have no conflict to declare.could be mono- or dizygotic twins. We noted a family
history of acne in the father and oldest brother. The
twin brothers had been treated with monthly in-
jections of testosterone for delayed puberty starting
at the age of 17. Under treatment, the testosterone
level reached normal range. Nine months later,
nodular and necrotic acne lesions suddenly devel-
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Table I. Demographic and clinical data of patients with testosterone-induced acne fulminans
Reference Sex
No. of
patients Age Clinical context Therapeutic regimen
Therapy received for acne
fulminans
Genetic Disorders
Hartmann
and Burg, 19891
M 1 19 Klinefelter syndrome Testosteron enantat
500 mg every 2 wk
over 18 mo
Isotretinoin therapy
over 16 weeks
Wollina et al, 20054 M 1 12 Marfan syndrome Testosterone 50 mg
every 2 wk for 6 mo
Clindamycin 300 mg,
prednisolone 1 mg/kg,
and isotretinoin
0.5 mg/kg.
Prednisolone switched
for dapsone 100 mg/d
(disagreement of
patient’s mother to
continue steroid
treatment)
Current case M 2 18 Kallmann syndrome Testosterone 250 mg
once a mo
over 10 mo
Systemic corticosteroid
0.5 mg/kg/d,
isotretinoin
0.06 mg/kg/d
Tall Stature Treatment
Traupe et al, 19882 M 3 13-16 Excessively tall
stature
High doses of
testosterone
Oral isotretinoin and
topical steroid (2 cases)
Systemic corticosteroid
(1 case)
Weimann
and Bohles, 19993
M 1 13 Hereditary tall stature
treated with high
dose of testosterone
Testosterone 250 mg
once a wk over 6 mo
Isotretinoin therapy
(0.3 mg/kg/d),
methylprednisolone
and cefaclor
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development of these lesions was associated with
generalmalaise but no fevers ormusculoskeletal pain.
The injections of testosterone were discontinued.
Simultaneously, severe nodular acne developed on
the back of the twin brother, which was treated in
another center using lymecycline, 300 mg/d, and
topical treatment. Given the interest of these rare
cases, cultures of the back lesions were taken. Results
showed the presence of fully susceptible P acnes
belonging to phylotype II in our patient and phylo-
type IB in his twin. Corticosteroid therapy (0.5mg/kg/
d)was initiated, resulting in disappearanceof necrotic
lesions at 1 month, allowing initiating tapering of
corticosteroids and introducing a very low dose of
isotretinoin (5 mg/d = 0.06 mg/kg/d). After 2 months
of isotretinoin treatment, the severe ulcerative acne
lesionswere significantly reduced (bymore than50%)
leaving atrophic scars. Corticosteroids were discon-
tinued, and isotretinoin dose was increased to 10 mg/
d. The treatment is still ongoing. Because acne
fulminans is a rare adverse event of testosterone
therapy, the case was reported to the clinical phar-
macology department.DISCUSSION
A few cases of testosterone-induced acne
fulminans have been described in the literature
(Table I), but this is the first case reported in
twins.1-4 These types of cases have been described
only in 2 situations: self-medication of anabolic
steroids in bodybuilders5 or testosterone treatment
given for excessively tall stature.1-4 Acne fulminans
appeared between 3 and 18 months after initiating
the treatment with testosterone in 5 cases and after
the end of the treatment in 1 case.3 This delay could
be due to the time necessary for the testosterone
treatment to accumulate in the blood to a level
triggering skin androgen receptors. The 2 genetic
cases are similar to that of our patient. The first one
was a 19-year-old boy with Klinefelter syndrome1
and the second one was a 12-year-old boy
with Marfan syndrome,4 both with tall stature and
treated with testosterone. In a large prospective
study, 23 boys treated with androgens (Triolandren)
in the context of an expected body height of more
than 200 cm (but without a known genetic dis-
order), severe acne developed in 5 patients and
progressed toward acne fulminans in 1.6 According
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imately 4%.
The identification of 2 different phylotypes of P
acnes in our cases does not suggest a relationship
between acne fulminans and a specific P acnes
cluster. It could be assumed that the treatment
increased the level of free testosterone in the blood
and thus in the skin. This testosterone increase could
have activated the skin androgen receptors. In the
context of twins, a genetic factor (mutation in the
androgen receptor gene) could have played a role.
The possible role of genetic factors influencing acne
is based first on the observation that a family history
of acne could be associated with an increased risk of
acne. Second, a large twin study including 458 pairs
of monozygotic and 1099 pairs of dizygotic twins
found that 81% of the acne variance was attributable
to additive genetic effects.7 Three reports of acne
fulminans in twins are published in the literature.
The first report presented 14-year-old monozygotic
twin boys born in Tenerife (Spain) with no family
history of acne fulminans.8 The second publication
detailed the case of a different set of 15-year-old
twin boys, also from Tenerife, who both had
acne fulminans. The outcome was favorable with
isotretinoin treatment in both patients and prednis-
olone treatment in the first twin.9 A third case
was reported in a brother and sister with the same
human leukocyte antigen type, supporting a
genetic predisposition.10 Our observation of acnefulminans in twins triggered by testosterone treat-
ment strengthens the hypothesis of a genetic abnor-
mality in connection with skin androgen receptors.
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